Etigilimab Active Not Recruiting Phase 2 Trials for Recurrent Platinum-Resistant Ovarian Carcinoma / Recurrent Primary Peritoneal Clear Cell Adenocarcinoma / Recurrent Ovarian Clear Cell Adenocarcinoma / Recurrent Fallopian Tube Clear Cell Adenocarcinoma / Recurrent Platinum-Resistant Primary Peritoneal Carcinoma / Recurrent Platinum-Resistant Fallopian Tube Carcinoma Treatment
clinicaltrials.gov Identifier | Title | Drugs |
---|---|---|
NCT05026606 | Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |